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Abstract
Background: Clefts of the lip, alveolus, and palate (CLPs) rank among the most frequent and
significant congenital malformations. Leu10Pro and Arg25Pro polymorphisms in the precursor
region and Thr263Ile polymorphism in the prodomain of the transforming growth factor β1 (TGF-
β1) gene have proved to be crucial to predisposition of several disorders.
Methods: In this study, polymorphism analysis was performed by real-time polymerase chain
reaction (LightCycler) and TGF-β1 levels determined by enzyme-linked immunosorbent assay.
Results: Only 2/60 Caucasian non-syndromic patients with CLP (3.3%) carried the Arg25Pro and
another 2/60 patients (3.3%) the Thr263Ile genotypes, whereas, in a control group of 60 healthy
Caucasian blood donors, these heterozygous genotypes were more frequent 16.7% having
Arg25Pro (10/60; p < 0.035) and 10,0% having Thr263Ile (6/60), respectively. TGF-β1 levels in
platelet-poor plasma of heterozygous Arg25Pro individuals were lower than those of homozygous
members (Arg25Arg) in the latter group, but this discrepancy narrowly failed to be significant.
Although polymorphisms in codon 10 and 25 were associated with each other, no difference was
found between patients and controls concerning the Leu10Pro polymorphism.
Conclusions: The genetic differences in codons 25 and 263 suggest that TGF-β1 could play an
important role in occurrence of CLP, however, functional experiments will be required to confirm
the mechanisms of disturbed development.
Background
Clefts of the lip, alveolus, and palate (CLPs) rank among
the most frequent and significant congenital malforma-
tions. The incidence of about 1:3000 in Africa differs from
the rate in Europe (1:500), Asia (1:350), and with the
American Indians (1:150) [1]. Concerning non-syndro-
mic clefts the underlying etiology remains unknown, but
both environmental as well as genetic factors are consid-
ered to be involved [2]. Critical periods for development
of CLP (Figs. 1A,1B,1C) are between the 36th and 42nd
day of embryogenesis and between the 49th and 58th day
for development of isolated cleft palates (Fig. 1D).
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Linkage studies in affected families have implicated sev-
eral chromosomal regions that might harbour predispos-
ing genes. These regions include chromosomes 2p13, 4q,
6p23, and 19q13 [2]. Analysis of segregation emphasized
that occurrence of CLPs is due to a combination of multi-
factorial inheritance and major genetic effect [3-5].
The TGF-β superfamily consists of more than 35 members
and represents a large group of extracellular growth factors
controlling many aspects of development [6]. There is no
sequential homology with transforming growth factor α
and its analogue epidermal growth factor. The TGF-β iso-
forms show a pronounced amino acid homology within
the mature C-terminal portion of the molecule and are
highly conserved throughout evolution [7]. Homo- or
hetero-dimers of the TGF-β family ligands bind to and
activate two types of transmembrane serine/threonine-
kinase-receptors, which then stimulate downstream regu-
latory Smad proteins to migrate from the cytoplasm to the
nucleus where they can function as transcriptional regula-
tors. There are three isoforms of TGF-β in humans. The 25
kb TGF-β1 locus (TGFB1) was assigned to 19q13.1 in man
[8]. More than 50% of TGF-β1 knockout mice die during
embryogenesis from yolk sac defects; survivors develop
inflammatory disorders and die typically within one
month [9]. In humans, mutations in the gene encoding
the latency-associated peptide of TGF-β1 lead to the
Camurati-Engelmann-syndrome [10-12], which is not
Patients with clefts Figure 1
Patients with clefts: (A) incomplete unilateral cleft of the lip, (B) unilateral cleft of the lip, alveolus, and palate, (C) bilateral 
cleft of the lip, alveolus, and palate, (D) isolated (median) cleft palate.
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associated with cleft formation [13,14]. Human TGF-β2-
gene maps to 1q41 [15]. Lack of TGF-β2 is perinatally
lethal and various craniofacial defects, axial and appen-
dicular skeletal defects are evident in TGF-β2 null mice
[16]. The TGF-β3 gene is localized to 14q24 in man and
lack of TGF-β3 is also perinatally lethal [15]. Cleft palate
and delayed lung development are obvious in TGF-β3
null mice [17,18].
TGF-β isoforms are translated as prepropeptide precursors
with an N-terminal signal peptide followed by the prodo-
main and mature domain and are secreted as biologically
latent forms [6]. The Leu10Pro-(T869C) and Arg25Pro-
(G915C) polymorphisms in exon 1 of the TGF-β1 gene
are located in the signal peptide sequence that is cleaved
from the TGF-β1 precursor at the level of codon 29 [19].
The signal sequence allows export of the newly synthe-
sized protein across the membranes of the endoplasmic
reticulum. Whereas both leucine and proline are apolar,
the Arg25Pro polymorphism corresponds to a change of
the big polar amino acid arginine for the small apolar pro-
line closely to the 3' end of the hydrophobic core of the
signal sequence. Polymorphisms in the TGF-β1 gene have
a significant genetic contribution to the control of TGF-β1
concentration and it was demonstrated that a
homozygous (Arg25Arg) genotype is associated with
higher TGF-β1 level than a heterozygous (Arg25Pro) gen-
otype [20]. Therefore, the correlation between that genetic
polymorphism in TGF-β1 gene and disease status has
been studied in a diverse range of diseases [19,21,22]. The
Thr263Ile-(C788T) polymorphism is located in exon 5
and codes for that part of the TGF-β1 proprotein that is
cleaved from the active part at the level of amino acid 278
[19]. It is conceivable that the substitution of the polar
amino acid threonine by the apolar isoleucine at codon
263 affects the stability and the activation process of TGF-
β1 leading to reduced concentrations of latent and subse-
quently active TGF-β1 [23]. The aim of this study was to
evaluate the correlation of the Leu10Pro, Arg25Pro, and
Thr263Ile polymorphisms in the TGF-β1-gene with the
evidence of non-syndromic CLP.
Methods
Patients and Sample Collection
All Caucasian patients suffering from CLPs and consulting
the University Hospital of Aachen between October 2002
and November 2003 were included in this study, but all
relatives of one patient who already had been considered,
were rejected to avoid misrepresentation due to hereditary
accumulation. Patients with known cleft-associated syn-
dromes as DiGeorge syndrome, Nager syndrome, Pierre
Robin sequence, Stickler syndrome, and van der Woude
syndrome were also excluded. As these syndromes are
most often accompanied by isolated (median) clefts of
the hard and soft palate, patients with such clefts were
omitted too, to escape accidental inclusion of syndromic
microforms. All patients or their parents had given their
informed consent to participate in this study which had
been approved by an appropriate institutional review
board. The CLPs were grouped into unilateral or bilateral
clefts of the lip, or lip and alveolus, or lip, alveolus, and
palate (Table 1). Males were more often affected by CLPs
than females (ratio: 36:24). In addition, unilateral clefts
were more often located on the left than on the right side
(ratio: 29:14). The youngest patient was 4 months, the
oldest 52 years of age, corresponding to a mean value of
14.1 years and a standard deviation of 12.4 years.
Table 1: Localization of clefts in the patient group.
Localization of clefts Number of patients
Lip left 3 Σ = 4
right 1
bilateral 1 1
Lip and alveolus left 4 Σ = 6
right 2 Σ = 60
bilateral 1 1
Lip, alveolus, and palate left 22 Σ = 33
right 11
bilateral 15 15BMC Medical Genetics 2004, 5 http://www.biomedcentral.com/1471-2350/5/15
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Sixty healthy Caucasian blood donors served as a control
group. Special attention was given to the fact that none of
these blood donors or their relatives was contracted by
clefts. The sexual ratio of the control group did not differ
significantly from the patient group (35 males/25
females), whereas the mean age was 24.3 years with a
standard deviation of 5.2 years.
Blood-samples were taken by venipuncture and stored on
ice for a maximum of 30 min using EDTA as anticoagu-
lant. For enzyme-linked immunosorbent assay (ELISA),
centrifugation was performed for 10 min at 1000 g and
4°C. The supernatants were centrifuged again for 10 min
at 10000 g and 4°C for complete platelet removal and
stored at -80°C in aliquots.
Genotyping
DNA was extracted from peripheral blood cells using the
QIAamp DNA Blood Mini extraction kit (Qiagen, Hilden,
Germany). The defined single-nucleotide polymorphisms
T869C and G915C in exon 1 and C788T in exon 5 of the
human TGF-β1 gene were genotyped in a LightCycler
(LC)-system (Roche Diagnostics, Basel, Switzerland) as
previously described [22]. Briefly, patients sample DNA
(approximately 80 ng) was first amplified in the presence
of primer for-1 [5'-d(CTA GGT TAT TTC CGT GGG)-3']
and primer rev-1 [5'-d(CCT TGG CGT AGT AGT CG)-3'],
or primer for-2 [5'-d(AAGCAGGGTTCACTACCGGC)-3']
and primer rev-2 [5'-d(AGG CCT CCA TCC AGG CTA
CA)-3']. Subsequently, the amplicons were analyzed by
different combinations of anchor and sensor probes.
These were: Leu10Pro-anchor probe [5'-d(TCC CCC ATG
CCG CCC TCC GGG CT-3')-fluorescein], Leu10Pro-sen-
sor probe [LC-Red640-5'-d(CGG CTG CTG CCG CTG CT-
Ph)-3'], Arg25Pro-sensor probe [LC-Red640-5'-d(ACG
CCT GGC CCG CCG-Ph)-3'], Arg25Pro-anchor probe [5'-
d(GCT ACC GCT GCT GTG GCT ACT GGT GCT-3')-fluo-
rescein], Thr263Ile-anchor probe [LCRed640-5'-d(GAG
AGG GCC CAG CAT CTG CAA AGC T-Ph)-3'], and
Thr263Ile-sensor probe [5'-d(ATG GCC ACC CCG CT-3')-
fluorescein], respectively.
Sequence Analysis
Sequencing reactions of cloned DNA fragments were per-
formed essentially as described previously using the Big
Dye®-Termination-Cycle-Sequencing-Ready-Reaction-kit
(Applied Biosystems, Weiterstadt, Germany) [24].
ELISA
Active plus acid-activatable latent TGF-β1, TGF-β2, and
TGF-β3 were measured in platelet-poor plasma. The
assays for detection of TGF-β1 (DB100), TGF-β2 (DB250),
and TGF-β3 (DY243) were purchased from R&D Systems
(Minneapolis, MN) and measurements were carried out
in accordance with the manufacturer's instructions.
Statistical Analysis
Statistical analysis was performed using Statistica 6.1 for
Windows (StatSoft, Tulsa, OK) data analysis software sys-
tem. A probability level of p < 0.05 was regarded as statis-
tically significant in all tests.
Results
Active and acid-activatable TGF-β1 was detectable in
platelet-poor plasma of all included patients by ELISA.
The mean value was 2.715 ng/ml with a standard devia-
tion of 1.622 ng/ml and a range from 0.812 ng/ml to
8.104 ng/ml. There was no correlation with age, gender,
and type of clefts. In the control-group TGF-β1 plasma lev-
els did not differ significantly from the patients group
showing a mean value of 2.756 ng/ml, a standard devia-
tion of 1.507 ng/ml, a minimum of 0.945 ng/ml, and a
maximum of 7.786 ng/ml. Again, there was no significant
correlation with gender and age. The ELISA-technique
used in this study resulted in very low levels of TGF-β2
and TGF-β3 below 0.2 ng/ml in plasma samples making a
comparison between both groups unfeasible.
Only 2/60 patients (3.3%), both suffering from bilateral
CLPs, showed the heterozygous Arg25Pro-genotype in the
TGF-β1 gene as determined by real-time polymerase chain
reaction (LightCycler; Fig. 2), whereas all of the others
(96.7%) were homozygous (Arg25Arg; Table 2). The TGF-
β1 plasma concentrations of these patients were 0.968
and 2.156 ng/ml respectively. In contrast, in the control
group, the Arg25Pro genotype was discovered in 10 cases
(16.7%) and Arg25Arg in the other 50 (83.3%). This rep-
resents a significant difference in Yates corrected Chi-
square test at a significance level of p < 0.035. TGF-β1 con-
centrations of heterozygous individuals were notably
lower than those of homozygous in the control group, but
this difference narrowly failed to be significant (Fig. 3).
The exchange of leucine by proline at codon 10 was signif-
icantly positively correlated with the Arg25Pro genotype
in both groups (p < 0.025). In particular, the occurrence
of the homozygous Leu10Leu genotype excluded the
simultaneous presence of the heterozygous Arg25Pro gen-
otype, but there was no difference depending on affection
by clefts (Table 3).
Two of the 60 patients (3.3%), one with a bilateral and
one with a unilateral left-sided CLP, showed the hetero-
zygous Thr263Ile genotype, whereas all of the others
(96.7%) were homozygous (Thr263Thr; Table 2). The
TGF-β1 plasma concentrations of these heterozygous
patients were 1.832 and 0.994 ng/ml respectively. Both
patients were non-identical with the two heterozygous
Arg25Pro patients. In the control group 6/60 individuals
(10,0%) were heterozygous (Thr263Ile) whereas all of the
others (90.0%) were revealed to be homozygousBMC Medical Genetics 2004, 5 http://www.biomedcentral.com/1471-2350/5/15
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Molecular analysis of the TGF-β1 allele variations at codon 25 Figure 2
Molecular analysis of the TGF-β1 allele variations at codon 25: (A) representative derivative melting curves of a rep-
resentative LightCycler run for analysis of the Arg25Pro gene polymorphism in the TGF-β1 gene. Samples shown are: no tem-
plate control (blue line) Arg25Arg (red line), Arg25Pro (black line), respectively. The amplified products of this LC run were 
separated in a 1.5% agrose gel showing the expected amplicon 523-bp in size (inlet). (B) Sequence analysis of the Arg25Pro 
alleles. 80 ng genomic DNA from a patient having a heterozygous allele constellation was taken as template in standard PCR 
and amplified using primers Arg25Pro-for and Arg25Pro-rev. Amplified DNA was gel purified, cloned into the pGEM-T Easy 
vector, and sequenced with primer Arg25Pro-for on the sense strand on the ABI PRISM310 Genetic Analyzer. The upper 
chromatogram was derived from the Arg25-allele, the lower chromatogram from the Pro25-allele. Amino acids Arg25 or 
Pro25 encoded by the polymorphic site (CGG or CCG) are boxed.
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Table 2: There was a significant difference in Arg25Pro polymorphism between patient and control groups using Yates corrected Chi-
square test (p < 0.035). The different distribution at codon 263 failed to be significant, but summarizing the individuals, who were 
homozygous at both codons, compared with individuals, who where heterozygous either at codon 25 or at codon 263 or at both codons, 
the difference between the patient and control groups was even more striking (p < 0.015).
Patients Controls
Arg25Arg 58 50
Arg25Pro 2 10
Thr263Thr 58 54
Thr263Ile 2 6
Arg25Arg and Thr263Thr 56 45
Arg25Pro and/or Thr263Ile 4 15
Plasma levels of TGF-β1 determined in ELISA were distinct between homozygous Arg25Arg and heterozygous Arg25Pro indi- viduals in the control group Figure 3
Plasma levels of TGF-β1 determined in ELISA were distinct between homozygous Arg25Arg and hetero-
zygous Arg25Pro individuals in the control group. But this difference narrowly failed to be statistically significant (Mann-
Whitney U test).
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(Thr263Thr). One of these heterozygous controls simulta-
neously was heterozygous at codon 25 and showed the
lowest TGF-β1 plasma concentration of all individuals in
this group.
Summarizing all individuals who were heterozygous
either at codon 25 or at codon 263, or at both of these loci
in that single case, the difference between the patients
group with 4/60 heterozygous cases (6.7%) and the con-
trols with 15/60 heterozygous cases (25.0%) was even
more striking (p < 0.015) than considering the Arg25Pro
polymorphism alone (Table 2).
Discussion
The temporal and spatial separate distribution of TGF-β
isoforms in the developing palate suggests an important
isoform-specific role in this developmental process, par-
ticularly as they exert several biological activities that con-
trol cell proliferation, migration, differentiation,
regulation of extracellular matrix deposition, and epithe-
lial-mesenchymal transformation [25]. Mice lacking TGF-
β3 exhibit an incompletely penetrant failure of the palatal
shelves to fuse leading to cleft palate. The defect appears
to result from impaired adhesion of the apposing medial
edge epithelia of the palatal shelves and subsequent elim-
ination of the mid-line epithelial seam by apoptosis
[17,18]. No craniofacial abnormalities were observed,
demonstrating that TGF-β3 inhibits palatal shelf fusion by
a primary mechanism rather than by effects due to cranio-
facial defects as in TGF-β2 null mice showing clefts in only
23% [16]. In contrast, TGF-β1 knockout mice never
develop any kind of CLP [9]. Moreover, a human in vitro
model gave evidence that TGF-β1 and TGF-β3 are differ-
ently expressed in normal as well as cleft palatal fibrob-
lasts suggesting that both isoforms may exert distinct or
even antagonistic functions [26].
The very low plasma concentrations of TGF-β2 and TGF-
β3 determined by ELISA are in agreement with previous
studies [27]. Though the levels of TGF-β1 protein in
plasma have been measured in a lot of studies to date, the
reported mean values range from 0.1 ng/ml to more than
25 ng/ml. There is a large number of factors, which is
likely to contribute to the great variance of described TGF-
β1 protein concentrations in plasma from healthy indi-
viduals. One of the most important seems to be the
method used to prepare the plasma samples because it is
difficult to prevent a small amount of platelets from
degranulation during sample collection and plasma prep-
aration, and platelets are a rich source of TGF-β1. Meas-
urements of plasma levels of TGF-β1 therefore require the
use of specific protocols designed to minimize platelet
degranulation [28]. However, most likely the variation in
reported plasma TGF-β1 concentrations is due to the
selection of different assay methods. Therefore, it is neces-
sary to compare the results with a control group tested
under equivalent conditions.
Furthermore, it is difficult to speculate on the biological
implications of TGF-β1 levels in plasma, particularly
regarding the nature of the complexes present [27]. Tissue
levels in critical periods for the development of CLPs dur-
ing embryogenesis could be completely different from
postnatal plasma concentrations and it is not necessarily
possible to deduce the biological activity. Thus, a geneti-
cally based technique should yield more reliable results as
this was described in hypertension [19], myocardial inf-
arction [19], atherosclerosis [29], colon [30], breast [31],
Table 3: No significant difference in Leu10Pro polymorphism between patient and control groups could be revealed, although the 
exchange of leucine by proline at codon 10 was positively correlated with Arg25Pro genotype calculated by Yates corrected Chi-square 
test (p < 0.025).
Cleft patients
Leu10Leu Leu10Pro Pro10Pro
Arg25Arg 19 30 9
Arg25Pro 0 2 0
Sum 19 32 9
Controls
Leu10Leu Leu10Pro Pro10Pro
Arg25Arg 22 24 4
Arg25Pro 0 8 2
Sum 22 32 6BMC Medical Genetics 2004, 5 http://www.biomedcentral.com/1471-2350/5/15
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and ovarian [32] cancers, diabetic nephropathy [33],
asthma [34], multiple sclerosis [35], and liver fibrosis
[22]. Interestingly, polymorphisms in the TGF-β1 gene
showed no correlation with the severity of symptoms of
the Camurati-Engelmann-disease [36].
Conclusions
The distribution of gene polymorphisms in our control
group totally agrees with those of the studies mentioned
above. No distinction in TGF-β1 plasma concentration
was provable between patients with CLPs and controls.
Nevertheless, the genetic divergence in TGF-β1
polymorphism suggests that TGF-β1 could play an impor-
tant role in occurrence of CLP. It is of special interest in
this context that the TGF-β1-locus at 19q13.1 [8] is con-
gruent with one chromosomal region (19q13) that might
harbour predisposing genes according to linkage studies
in affected families [2]. Taking into account that TGF-β1
concentration depends on Arg25Pro and Thr263Ile poly-
morphisms in the TGF-β1-gene and is lower in hetero-
zygous individuals, CLPs may develop more frequently
under increased influence of TGF-β1, however, functional
experiments will be required to confirm the mechanisms
of disturbed orofacial development.
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